Michael Asbach,

DMSc, PA-C, Psych-CAQ

Michael Asbach,

DMSc, PA-C, Psych-CAQ

Michael Asbach,

DMSc, PA-C, Psych-CAQ
Associate Director, Interventional Psychiatry, DENT Neurologic Institute

Michael Asbach, DMSc, PA-C, Psych-CAQ, is the associate director of interventional psychiatry at DENT Neurologic Institute. He is a clinical professor of psychiatry at Daemen College, D’Youville University, and Rochester Institute of Technology. Dr. Asbach received his master’s degree in physician assistant studies from Daemen College. His Doctorate of Medical Science degree is with a concentration in healthcare leadership. Dr. Asbach is a member of the American Academy of Physician Assistants and the Association of Physician Assistants in Psychiatry, and he serves as the Chair of Industry Relations for the New York State Society of Physician Assistants. Dr. Asbach is a nationally recognized educator who has provided more than 400 lectures on behalf of the pharmaceutical industry and medical education companies.

Michael's Shared Resources

FDA Accepts New Drug Application for Xanomeline-Trospium

Karuna Therapeutics announced that the FDA accepted their New Drug Application for KarXT (xanomeline-trospium), a treatment for schizophrenia in adults...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ

Danish Study Finds Higher Schizophrenia Risk in Young Males With Cannabis Use Disorder

In a study, researchers focused on the relationship between cannabis use disorder (CUD) and schizophrenia, particularly in males. It was...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ

“My 2-Minute Neuroscience” Video Explores Schizophrenia’s Complex Neurobiology

A recent two-minute video touches on the Neuroscientific research on schizophrenia that has mainly focused on neurotransmitter abnormalities, particularly dopamine,...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ

New Promising Drugs in Schizophrenia Treatment Discussed by Expert Roundtable

An expert roundtable discussed various promising drugs with novel mechanisms, such as ulotaront (a TAAR1 agonist and 5-HT1A agonist) from...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ

Schizophrenia Treatments Target Muscarinic Receptors, Promising Personalized Approaches

A study emphasized the importance of muscarinic M1 and M4 receptors in treating schizophrenia, with new medications like KarXT and...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ

Machine Learning Improves Schizophrenia Diagnosis

In a recent study involving 72 schizophrenia patients and 74 healthy control subjects using structural magnetic resonance imaging data, various...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ
Share